A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 30 Mar 2021 According to a Jazz Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older.The approval of Vyxeos for this indication is supported by safety data from two single-arm trials (AAML1421 and CPX-MA-1201).
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.